From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Zika: Study Finds Antibody That Protects Against Fetal Disease

by Global Biodefense Staff
November 8, 2016
James Crowe Jr Vanderbilt Vaccine Center

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center. Credit: Vanderbilt University Medical Center

James Crowe Jr Vanderbilt Vaccine Center
James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center. Credit: Vanderbilt University Medical Center

Administering a human antibody that neutralizes Zika virus to pregnant mice before or after Zika virus infection reduced levels of the virus in placental and fetal tissues and decreased fetal disease, new findings show. The work may aid development of vaccines and therapies for Zika virus infection, which can cause severe birth defects when it occurs during pregnancy.

The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by scientists at Vanderbilt University, Washington University School of Medicine and Integral Molecular, a Philadelphia biotechnology company.

The researchers isolated immune B cells from the blood of three people with prior Zika virus infections, generated antibodies from these cells and characterized antibodies that bind to Zika virus proteins. One antibody, named ZIKV-117, neutralized all strains of Zika virus tested, including African, Asian and American lineages. Male mice that received a single dose of ZIKV-117 even five days after Zika infection were more likely to survive than those given a control antibody, suggesting that ZIKV-117 could treat active Zika infection.

The researchers next found that ZIKV-117 had protective effects during pregnancy. Pregnant mice that received the antibody and were then infected with Zika virus had lower levels of Zika virus in their blood and brain tissues than mice not treated with ZIKV-117. Among the treated mice, the scientists found protective levels of ZIKV-117 in fetal tissues and markedly reduced levels of virus in the placenta and the fetal brain.

Taken together, these findings suggest that ZIKV-117 may reduce mother-to-fetus virus transmission and also neutralize Zika virus that reaches the fetus. The researchers saw similar effects when they administered ZIKV-117 to pregnant mice immediately after the animals were infected with Zika virus. The reduced viral loads were associated with less placental injury and larger fetus size.

“These naturally occurring human antibodies isolated from humans represent the first medical intervention that prevents Zika infection and damage to fetuses,” said James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center and co-corresponding author of the paper with Michael S. Diamond, M.D., Ph.D., at Washington University.

Similar protection studies in primates are warranted, and if the findings hold up, ZIKV-177 or similar antibodies could be developed as a protective antibody treatment for pregnant women at risk of Zika infection, the researchers concluded.

In addition, the findings may inform the design of vaccines that elicit protective neutralizing antibodies against Zika virus.

“The remarkable potency and breadth of inhibition by ZIKV-117 has great promise,” Diamond said, “as it was able to inhibit infection by strains from both Africa and America in cell culture and in animals, including during pregnancy.”

Read more: G Sapparapu et al. Neutralizing human monoclonal antibodies prevent Zika virus replication and fetal disease in pregnancy. Nature DOI: 10.1038/nature20564 (2016).

From Our Partners
Tags: Emerging ThreatsZika

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC